Global availability of data on HPV genotype-distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females

Abstract

BackgroundCountry-level HPV genotyping data may be sought by decision-makers to gauge the genotype-specific burden of HPV-related diseases in their jurisdiction and assess the potential impact of HPV vaccines. We investigated, by country, the availability of published literature on HPV genotypes in cervical, vaginal and vulvar cancers and intraepithelial neoplasms (CINs, VaINs and VINs) and on prevalence and incidence of genital HPV infections among women without clinically manifest disease.FindingsPrimary sources of publications were the PubMed/Medline and EMBASE databases. Original studies or meta-analyses published from 2000, covering genotypes 16 and 18 and at least one of genotypes 31/33/45/52/58, were included. Key exclusion criteria were language not English, cervical lesions not histologically confirmed (cytology only), special populations (e.g., immunocompromised) and, for cervical studies, small population (<50). A total of 727 studies reporting HPV genotype-specific data were identified: 366 for cervical cancers and CINs, 43 for vulvar or vaginal cancers and VINs/VaINs, and 395 and 21 for infection prevalence and incidence, respectively, in general female population samples. A large proportion of studies originated from a small set of countries. Cervical cancer/CIN typing data was scarce for several regions with the highest cervical cancer burden, including Eastern, Middle and Western Africa, Central America, South-East Asia, South Asia, and Eastern Europe. Data for vulvar/vaginal disease was limited outside of Europe and North America.ConclusionsAlthough a large body of published HPV genotype-specific data is currently available, data gaps exist for genotype-specific infection incidence and several world regions with the highest cervical cancer burden.Electronic supplementary materialThe online version of this article (doi:10.1186/s13027-015-0008-y) contains supplementary material, which is available to authorized users.

Expression analysis of transglutaminase 2 in premalignant lesions of the cervix

“…The presence of HPV in normal samples is also shown in other studies [2,22,23]. In a study performed in the city of Porto Alegre, the prevalence of HPV was demonstrated in 11.6% of women without LSIL or HSIL [25].…”

“…Among the most common HPV types, genotypes 16, 18, 31, 33, 45, 52 and 58 are responsible for approximately 90% of cervical cancers [22]. In Brazil, Oliveira et.…”

Prevalence of Cervical Infection and Genotype Distribution of Human Papilloma Virus Among Females in Da Nang, Vietnam

“…There are a number of variants such as monovalent (HPV16), bivalent (HPV16 and 18), quadrivalent (HPV6, 11, 16 and 18) and nonavalent (HPV6,11,16,18, 31, 33, 45, 52 and 58) vaccines (5,6). In Vietnam, the measures for cervical cancer prevention include, primary screening for HPV and vaccination against HPV (7).…”

HPV infection of the cervix uteri: Prospects for combination treatment

“…Доказано, что самой распространенной патологией, ведущей к развитию пред-раковых заболеваний, является папилломавирусная ин-фекция (ПВИ), передающаяся половым путем [1][2][3][4][5][6][7][8].Невиданное доселе обновление технологического обеспечения, произошедшее на рубеже XX-XXI веков, совершенствование методов диагностики вирусных забо-леваний способствовали не только выявлению истинной частоты инфицированности вирусом папилломы челове-ка (ВПЧ), но и изучению связи между инфицированно-стью ВПЧ и диспластическими процессами шейки матки [8][9][10][11][12]. Доказано, что репликация ВПЧ на начальном эта-пе приводит к возникновению воспалительной реакции в шейке матки, а в последующем -к возникновению в тол-ще эпителиального слоя атипичных клеток с различной степенью нарушения их дифференцировки, к изменени-ям слоистости эпителиальных клеток (без участия в пато-логическом процессе стромальных структур).…”

“…(ПИП) [8][9][10][11][12]. Плоскоклеточное интраэпителиальное поражение шейки матки классифицируется как ПИП низкой (LSIL -low-grade squamous intraepithelial lesions) и высокой (HSIL-high-grade squamous intraepithelial lesions) степени выраженности в зависимости от уровня патоло-гического роста клеток.…”